IONS Stock Recent News

Ionis Pharmaceuticals (IONS -0.44%), a biotechnology company focused on RNA-targeted therapeutics, reported its second quarter 2025 earnings on July 30, 2025. The headline news was a substantial beat on both GAAP revenue and non-GAAP earnings compared to Wall Street estimates.

Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2025 Earnings Conference Call July 30, 2025 11:30 AM ET Company Participants Brett P. Monia - Founder, CEO & Director D.

Ionis Pharmaceuticals Inc. IONS reported second-quarter adjusted earnings of 85 cents on Wednesday. The company reported an adjusted loss of $35 million a year ago.

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to a loss of $0.45 per share a year ago.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025. “During the second quarter, we continued to build momentum across our business,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “Our strong performance included excellent commercial execution, resulting in a substantial increase in TRYNGOLZA revenues, our first independently launched med.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The positive opinion is now referred to the European Commission (EC) for an approval decision, which is expected by Q4.

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stanley Crooke, Ionis Pharmaceuticals founder and n-Lorem founder, joins 'Squawk Box' to discuss the fight against rare diseases, the development of ASO technology, and more.